Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Biol Psychiatry. 2011 Jan 1;69(1):71–79. doi: 10.1016/j.biopsych.2010.09.036

Figure 2. Expression of synaptic mRNAs in schizophrenia.

Figure 2

(A) The general synaptic mRNA VAMP1 and mRNAs enriched in inhibitory terminals (complexin 1 and vesicular GABA transporter, VGAT) or excitatory terminals (complexin 2 and vesicular glutamate transporter, VGluT1) are not significantly reduced in schizophrenia. (B) Plasticity and axon guidance associated mRNAs (growth associated protein 43, GAP43; and neuronal navigators 1 and 2, NAV1 and NAV2) are reduced in the DLPFC in schizophrenia compared to controls. Dysbindin mRNA expression is not altered overall in the schizophrenia cohort. *p<0.05 by Student's t-test, # p<0.05 by ANCOVA co-varying for pH. White bars controls, grey bars schizophrenia cases.